Azelastine

Drug Profile

Azelastine

Alternative Names: Afluon; Allergodil; Astelin; Astepro; Astepro Extra Strength; Astepro Once-Daily; Azelastine extra strength; Azelastine HCl; Azelastine hydrochloride; Azelastine nasal spray; MP03-33; MP03-36; Optilast; Optivar; Rhinolast

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Muro Pharmaceutical
  • Developer Meda
  • Class Antiallergics; Phthalazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 12 May 2014 Generic equivalent of Astepro® (intranasal) approved in USA for Allergic rhinitis
  • 20 Mar 2012 The EMA approves azelastine (improved formulation; Astepro®) for Allergic rhinitis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top